Şirin Uysal Ol

Şirin Uysal Ol

Auto-generated profile, based on publicly available information

Şirin Uysal Ol

Ege Universitesi

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SUSirin Uysal
Sirin Uysal
ZSZeynep SOYER
Zeynep SOYER
MSMerve Saylam
Merve Saylam
ATAyse H. Tarikogullari
Ayse H. Tarikogullari
SYSinem Yilmaz
Sinem Yilmaz
PKPetek Ballar Kirmizibayrak
Petek Ballar Kirmizibayrak

31 December 2025 in European Journal of Life Sciences
Verified
Journal Article
Closed access
ŞOŞirin Uysal Ol
Şirin Uysal Ol
ZSZeynep SOYER
Zeynep SOYER
Diabetes mellitus is a global health crisis, recognized as one of the 21st century’s most significant challenges. Therapeutic strategies for managing Type 2 Diabetes mellitus (T2DM) frequently involve α-glucosidase inhibitors (AGIs), which mitigate postprandial glucose excursions by delaying carbohydrate digestion. This study focuses on the synthesis, characterization, and in vitro α-glucosidase inhibitory evaluation of a novel phthalimido-benzenesulfonamide hybrid compound, specifically 4-phthalimido-N-(5-chloro-2-pyridylamino)benzenesulfonamide. Additionally, enzyme kinetics and molecular docking studies were performed on this compound to reveal enzyme inhibition models and ligand-enzyme binding interactions. Furthermore, we used the PreADMET web service to calculate the ADME/Tox properties of the compound. According to the biological activity data, the target compound exhibited α-glucosidase inhibition (IC50 = 1240.52 ± 316.98 µM) comparable to the reference drug acarbose (IC50 = 1210.96 ± 0.17 μM), positioning it as a promising scaffold for future antidiabetic drug development efforts. Molecular docking studies provided informative clues for the ligand-enzyme binding interactions to estimate allosteric cavities (A1-A5) of the homology model of α-glucosidase. Kinetic analysis revealed an uncompetitive inhibition, with reduced Kₘ and Vₘₐₓ, confirming an allosteric mechanism. In silico ADME/Tox predictions suggested that the compound had favorable ADME/Tox properties. Overall, this hybrid compound represents a promising lead for next-generation AGIs with reduced side effects.